



I fw

PATENT
Attorney Docket No. 09707.0007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Kazuo Umezawa et al.) Group Art Unit: Unassigned
)
Application No.: 10/567,432) Examiner: Unassigned
)
Filed: February 6, 2006)
)
For: MACROPHAGE ACTIVATION) Confirmation No.: Unassigned
INHIBITOR)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed foreign and non-patent literature documents are attached.
Copies of the U.S. patent publications are not enclosed.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

English translations of the non-English documents are enclosed.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed

documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: June 12, 2006

By: David W. Hill
David W. Hill
Reg. No. 28,220

IDS Form PTO/SB/08: Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 5


Complete if Known

| | |
|------------------------|----------------------|
| Application Number | 10/567,432 |
| Filing Date | February 6, 2006 |
| First Named Inventor | Kazuo Umezawa et al. |
| Art Unit | Unassigned |
| Examiner Name | Unassigned |
| Attorney Docket Number | 9707.0007 |

| U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS | | | | | |
|---|-----------------------|--|---|---|---|
| Examiner Initials | Cite No. ¹ | Document Number | Issue or Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | | US-6,566,394 B1 | 05/20/2003 | Takeuchi et al. | |
| | | US-2004/0259877 A1 | 12/23/2004 | Muto et al. | |
| | | US-5,804,374 | 09/08/1998 | Baltimore et al. | |
| | | US-6,150,090 | 11/21/2000 | Baltimore et al. | |
| | | US-6,410,516 B1 | 06/25/2002 | Baltimore et al. | |


Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---|--------------------------------|---|---|--------------------------|
| Examiner Initials | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | Translation ⁶ |
| | | Country Code ³ Number ⁴ Kind Code ⁵ (if known) | | | | |
| | | WO 00/26197 | 05/11/2000 | GU et al. | | |
| | | WO 99/65449 | 12/23/1999 | CALLAHAN et al. | | |
| | | WO 00/30587 | 06/02/2000 | HIRSCH et al. | | |
| | | WO 00/02548 | 01/20/2000 | MUNDY et al. | | |
| | | WO 00/61167 | 10/19/2000 | G. MUNDY | | |
| | | WO 01/47543 A2 | 07/05/2001 | FOXWELL et al. | | |
| | | JP 10-045738 | 02/17/1998 | T. TOMIO et al. | | |
| | | JP 09-157266 | 06/17/1997 | | | |
| | | WO 2004/002465 A1 | 01/08/2004 | K. UMEZAWA et al. | | |
| | | JP 63-178101 | 07/22/1988 | OKAMOTO et al. | | |
| | | JP 6-211902 | 08/02/1994 | O. YOSHIO | | |
| | | JP 2001-296288 | 10/26/2001 | O. ATSUSHI et al. | | |
| | | JP 2002-128690 | 05/09/2002 | H. TOSHINARI | | |
| | | WO 01/21206 A1 | 03/29/2001 | Y. NUNOKAWA | | |
| | | JP 2001-352986 | 12/25/2001 | O. Choei | | |
| | | JP 08-12574 | 01/16/1996 | | | |
| | | JP 10-251148 | 09/22/1998 | | | |
| | | JP 10-231247 | 09/02/1998 | | | |
| | | EP 1 010 435 A1 | 05/21/2000 | Y. IMASATO et al. | | |
| | | WO 99/15183 | 04/01/1999 | P. ELLIOT et al. | | |
| | | WO 01/28579 A2 | 04/26/2001 | G. MUNDY et al. | | |



| | | | | |
|--|-----------|----|--------------------------|----------------------|
| IDS Form PTO/SB/08: Substitute for form 1449A/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | Application Number | 10/567,432 |
| | | | Filing Date | February 6, 2006 |
| | | | First Named Inventor | Kazuo Umezawa et al. |
| | | | Art Unit | Unassigned |
| | | | Examiner Name | Unassigned |
| Attorney Docket Number | 9707.0007 | | | |
| Sheet | 2 | of | 5 | |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|--|--|--------------------------|
| Examiner Initials ⁵ | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | Translation ⁶ |
| | | M. SUMITOMO et al., "Induction of Apoptosis of Cytokine-Producing Bladder Cancer Cells by Adenovirus-Mediated IKB α Overexpression", Human Gene Therapy 10:37-47 (January 1999), pp. 37-47. | | |
| | | R. ROMIEU-MOUREZ et al., "Roles of IKK Kinases and Protein Kinase CK2 in Activation of Nuclear Factor- κ B in Breast Cancer", Cancer Research 61: May 2001, pp. 3810-3818. | | |
| | | J. YANG et al., "Constitutive I κ B Kinase Activity Correlates with Nuclear Factor- κ B Activation in Human Melanoma Cells", Cancer Research 61, June 2001, pp. 4901-4909. | | |
| | | N. NARA et al., "Elucidation of Cancer Cachexia-Inducing Factor--Focusing on Cytokines--", Saishin Igaku, Vol. 54, No. 10, 1999, pp. 2502-2507. | | |
| | | S. GHOSH et al., "NF- κ B and REL Proteins: Evolutionarily Conserved Mediators of Immune Responses", Annu. Rev. Immunol., 16, pp. 225-60, 1998. | | |
| | | N. MATSUMOTO et al., "Synthesis of NF- κ B Activation Inhibitors Derived from Epoxyquinomicin C", Biorg. Med. Chem. Letters 10, pp. 865-869, (2000). | | |
| | | A. BALDWIN, "Control of Oncogenesis and Cancer Therapy Resistance by the Transcription Factor NF- κ B", Journal of Clinical Investigation, Vol. 107, No. 3, February 2001, pp. 241-246. | | |
| | | G. ERKEL et al., "Inhibition of NF- κ B Activation by Panepoxydone", Biochemical and Biophysical Research Communications 226, (1996), pp. 214-221. | | |
| | | A. GEHRT et al., "Cycloepoxydon, 1-Hydroxy-2-hydroxymethyl-3-pent-1-enylbenzene and 1-Hydroxy-2-hydroxymethyl-3-pent-1,3-dienylbenzene, New Inhibitors of Eukaryotic Signal Transduction", The Journal of Antibiotics, Vol. 51, No. 5, February, 1998, pp. 455-463. | | |
| | | Yao-ZHONG LIN et al., "Inhibition of Nuclear Translocation of Transcription Factor NF- κ B by a Synthetic Peptide Containing a Cell Membrane-permeable Motif and Nuclear Localization Sequence", Journal of Biological Chemistry, Vol. 270, June 1995, pp. 14255-14258. | | |
| | | P. WIPF et al., "Synthesis of (—)-LL-C10037 α and Related Manumycin-Type Epoxyquinols", Synthesis, 1995, pp. 1549-1561. | | |
| | | A. ARIGA et al., "Inhibition of Tumor Necrosis Factor- α -induced Nuclear Translocation and Activation of NF- κ B by Dehydoroxy-methylepoxyquinomicin", The Journal of Biological Chemistry, Vol. 277, No. 27, July 2002, pp. 24625-24630. | | |
| | | J. MASFERRER et al., "Antiangiogenic and Antitumor Activities of Cyclooxygenase-2 Inhibitors", Cancer Research No. 60, March 2000, pp. 1206-1311. | | |
| | | T. TANAKA et al., "A Novel Monoclonal Antibody Against Murine IL-2 Receptor β -Chain Characterization of Receptor Expression in Normal Lymphoid Cells and EL-4 Cells", Journal of Immunology, Vol. 147, No. 7, October 1991, pp. 2222-2228. | | |
| | | K. UMEZWA et al., "Anticancer Agent-Resistant Factors", "8. Cell Cycle and Apoptosis-Related Factors", "Role and Inhibitors of Transcription Factor NF- κ B", Surgery Frontier, Vol. 9, No. 2, (2002), pp. 88-91. | | |
| | | A. ASEA et al., "Novel Signal Transduction Pathway Utilized by Extracellular HSP70", The Journal of Biological Chemistry, Vol. 277, No. 17, April 2002, pp. 15028-15034. | | |
| | | Z. YAN, "Benzo[a]pyrene Induces the Transcription of Cyclooxygenase-2 in Vascular Smooth Muscle Cells", Journal of Biological Chemistry, Vol. 275, No. 7, February 2000, pp. 4949-4955. | | |
| | | K. HISHIKAWA et al., "Towards Molecule Understanding of Drug Mechanism of Action and Biological Functions", "Transcription Factor NF- κ B as a Drug Target", Folia Pharmacol. Jpn., Vol. 118, (2001), pp. 197-202. | | |
| | | R. SEN et al., "Multiple Nuclear Factors Interact with the Immunoglobulin Enhancer Sequences," Cell, Vol. 46, August 1986, pp. 705-716. | | |
| | | A. BALDWIN, Jr., "The NF- κ B and I κ B Proteins: New Discoveries and Insights", Annu. Rev. Immunol. Vol. 14, (1996), pp. 649-81. | | |
| | | P. BAEUERIE et al., "NF- κ B: Ten Years After", Cell, Vol. 87, October 1996, pp. 13-20. | | |
| | | P. BAEUERIE et al., "Function and Activation of NF- κ B in the Immune System", Annual Review Immunol., Vol. 12, (1994), pp. 141-79. | | |
| | | R. TAYLOR, "The Synthesis of Alisamycin, Nisamycin, LL-C10037 α and Novel Epoxyquinol and Epoxyquinone Analogues of Manumycin A", Synthesis, (1998), pp. 775-790. | | |
| | | E. KIKUCHI et al., "Suppression of Hormone-refractory Prostate Cancer by a Novel Nuclear Factor κ B Inhibitor in Nude Mice", Cancer Research, 63, January 2003, pp. 107-110 | | |
| | | K. UMEZAWA et al., "Molecular Design and Biological Activities of NF- κ B Inhibitors", Mol. Cells, Vol. 14, No. 2, pp. 153-167. | | |



IDS Form PTO/SB/08: Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

3

of


5

Complete if Known

| | |
|------------------------|----------------------|
| Application Number | 10/567,432 |
| Filing Date | February 6, 2006 |
| First Named Inventor | Kazuo Umezawa et al. |
| Art Unit | Unassigned |
| Examiner Name | Unassigned |
| Attorney Docket Number | 9707.0007 |

NON PATENT LITERATURE DOCUMENTS

| | | |
|--|--|--|
| | C. CHAICHARONPONG et al., "Synthesis and Structure-Activity Relationship of Dehydroxymethylepoxyquinomicin Analogues as Inhibitors of NF-κB Functions", Bioorganic & Medicinal Chemistry 10 (2002), pp. 3933-3939. | |
| | K. UMEZAWA et al., "Naturally Occurring and Synthetic Inhibitors of NF-κB Functions", Anti-Cancer Drug Design (2000), 15, 239-244. | |
| | N. MATSUMOTO et al., "Inhibition of Rat Embryo Histidine Decarboxylase by Epoxyquinomicins", Vol. 53, No. 6, June 2000, pp. 637-639. | |
| | T. KASAHARA et al., "Anti-TNFα Antibody 1", "A Wide Spectrum of Physiological Activity of TNFα", Chiryogaku, Vol. 36, No. 12, (2002), pp. 1231-1234. | |
| | K. MURAKAMI et al., "Effects of TNF-α and Cellular Functions", The Lipid, Vol. 9, No. 5, 1998-10, pp. 479-485. | |
| | M. KOBAYASHI, Igaku no ayumi, (1998), 184(6), pp. 562-566. | |
| | H. SCHEDEL et al., "Synthesis of (R)-4,4,4-trifluoro-2-mercaptobutyric acid", Tetrahedron-Asymmetry, 2000, 11, pp. 2125-2131. | |
| | S. KURU et al., "TNF Expression in Muscular Disorder", Neuroimmunology Vol. 10, No. 1, (2002), pp. 174-175. | |
| | T. NAKAMURA et al., "Inhibitory Effect of New NF-κB Inhibitor DHM2e! for Human Breast Cancer Cells", Proceedings of the Japanese Cancer Association, the 61 st Annual Meeting, 2002, p. 157 (3550). | |
| | T. OHTSUKI et al., "Two Human Myeloma Cell Lines, Amylase-Producing KMS-12-PE and Amylase-Non-Producing KMS-12-BM, Were Established from a Patient, Having the Same Chromosome Marker, t(11;14)(q13;q32); British Journal of Haematology, (1989), 73, 199-204. | |
| | I. NONAKA, "Mechanism of Organogenesis", "Mechanism of Muscle Fiber Generation", Igaku no ayumi, 2001, 199(13), pp. 1045-1048. | |
| | Y. HORIGUCHI et al., "Antitumor Effect of a Novel Nuclear Factor-κB Activation Inhibitor in Bladder Cancer Cells", Expert Rev. Anticancer Ther. 3(6), 793-798 (2003). | |
| | C. CHAICHARONPONG et al., "Preparation of Radioactively Labeled Dehydroxymethyl-Epoxyquinomicin, An NF-κB Function Inhibitor", Drugs Exptl. Clin. Res. 2003; 29(1):1-3(2003). | |
| | A. MIYAJIMA et al., "Novel Nuclear Factor κB Activation Inhibitor Prevents Inflammatory Injury in Unilateral Ureteral Obstruction", The Journal of Urology, Vol. 169, April 2003, pp. 1559-1563. | |
| | YU-LI LIN et al., "(—)-Epigallocatechin-3-Gallate Blocks the Induction of Nitric Oxide Synthase by Down-Regulating Lipopolysaccharide-Induced Activity of Transcription Factor Nuclear Factor-κB", Molecular Pharmacology, Vol. 52, (1997), pp. 465-472. | |
| | B. OHLSSON et al., "Oxidized Low Density Lipoprotein Inhibits Lipopolysaccharide-Induced Binding of Nuclear Factor-κB to DNA and the Subsequent Expression of Tumor Necrosis Factor-α and Interleukin-1β in Macrophages", J. Clin. Invest., Vol. 98(1), (1996), pp. 78-89. | |
| | S. ELIGINI et al., "Oxidized Phospholipids Inhibit Cyclooxygenase-2 in Human Macrophages via Nuclear Factor-κB/κB- and ERK2-Dependent Mechanisms", Cardiovascular Research 55 (2002) 406-415. | |
| | A. ARIGA et al., Seikagaku, Journal of Japanese Biochemical Society, 73(8), 2001. | |
| | K. UMEZAWA, "New Molecular Targets of Antidiabetic Agents and Anticancer Agents and Inhibitors", The 2 nd Annual Report of the Center for the Development of Molecular Target Drugs, Symposium on Molecular Target Drugs in Kanazawa, 2002, Abstract. | |
| | K. UMEZAWA, "Role of Signal Transduction Inhibitors of Low Molecular Weight in Regenerative and Genetic Medicine", The 7 th Annual Scientific Meeting of Conference of Gene Therapy and Molecular Medicine, 2003, Abstract. | |
| | A. ARIGA et al., "Synthesis of Novel Epoxydone Compound DHM2EQ and Its Suppression of the NF-κB Action", The 4 th Annual Meeting of the Japanese Association for Molecular Target Therapy of Cancer, 2000, Abstract. | |
| | Y. SHIMA et al., "Inhibition by NF-κB Inhibitor DHMEQ of Adhesion Molecule Expression in Vascular Cells", The 6 th Annual Meeting of the Japanese Association for Molecular Target Therapy of Cancer, 2002, Abstract. | |
| | M. WATANABE et al., "Basic Studies of the Molecular Target Therapy of ATL Using a Novel NF-κB Inhibitor", The 6 th Annual Meeting of the Japanese Association for Molecular Target Therapy of Cancer, 2002, Abstract. | |
| | N. TAKAHASHI et al., "NF-κB Inhibition in Prostatic Cancer Cells and Anti-Cancer Activity by DHMEQ", The 7 th Annual Meeting of the Japanese Association for Molecular Target Therapy of Cancer, 2003, Abstract. | |
| | M. WATANABE et al., "Basic Studies of the Molecular Target Therapy of ATL Using Novel NF-κB Inhibitor", The 7 th Annual Meeting of the Japanese Association for Molecular Target Therapy of Cancer, 2003, Abstract S3-4. | |



Form PTO/SB/08: Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

4

of


5

Complete if Known

| | |
|------------------------|----------------------|
| Application Number | 10/567,432 |
| Filing Date | February 6, 2006 |
| First Named Inventor | Kazuo Umezawa et al. |
| Art Unit | Unassigned |
| Examiner Name | Unassigned |
| Attorney Docket Number | 9707.0007 |

NON PATENT LITERATURE DOCUMENTS

| | | |
|--|--|--|
| | H. TATETSU et al., "In Vivo and In Vitro Studies of Novel NF-κB Inhibitor (DHMEQ) in Myeloma Cells", 28 th Annual Meeting of Japan Myeloma Study Group, 2003, Abstract. | |
| | A. ARIGA et al., "Inhibition of NF-κB by a Novel Epoxydone Compound", Proceedings of the Japanese Cancer Association, the 59 th Annual Meeting, 2000, Abstract. | |
| | E. KIKUCHI et al., "Apoptosis-Induction in Hormone-Refractory Prostate Cancer Using a Novel NF-κB Activation Inhibitor", Proceedings of the Japanese Cancer Association, the 60 th Annual Meeting, 2001, Abstract. | |
| | Y. SHIMA et al., "Inhibition of Adhesion Molecule Expression by a NF-κB Inhibitor DHMEQ in Vascular Endothelial Cells", Proceedings of the Japanese Cancer Association, the 61 st Annual Meeting, 2002, Abstract. | |
| | J. NAMEKAWA et al., "Inhibition of NF-κB Activity in Bladder Carcinoma Cells", Proceedings of the Japanese Cancer Association, the 61 st Annual Meeting, 2002, Abstract. | |
| | M. WATANABE et al., "Basic Studies of the Molecular Target Therapy of ATL Using a Novel NF-κB Inhibitor", Proceedings of the Japanese Cancer Association, the 61 st Annual Meeting, 2002, Abstract p. 162 (3486). | |
| | G. MATSUMOTO et al., "NF-κB Inhibitor Enhances the Anti-Cancer Effect of TNF-α Treatment and Ionizing Radiation in p. 53 Wild Pancreatic Cancer", Proceedings of the Japanese Cancer Association, the 62nd Annual Meeting, 2003, Abstract p. 160(2073-OA). | |
| | R. HORIE et al., "Basic Studies of the Molecular Target Therapy of ATL Using a Novel NF-κB Inhibitor", Proceedings of the Japanese Cancer Association, the 62nd Annual Meeting, 2003, Abstract p. 153 (2039-OA). | |
| | E. SUZUKI et al., "Inhibition of Macrophage Activation by the Novel NF-κB Inhibitor, Dehydroxymethylepoxyquinomicin", 3 rd International Symposium on Natural Drugs, Naples, October 2-4, 2003, p. 100. | |
| | A. ARIGA et al., "Molecular Design and Biological Activities of a new NF-κB Inhibitor, Dehydroxymethylepoxyquinomicin (DHMEQ)", Keystone Symposia: NF-κB: Biology and Pathology 2002, Abstract. | |
| | E. SUZUKI et al., "Inhibition of Macrophage Activation by Dehydroxymethylepoxyquinomicin (DHMEQ), a novel NF-κB Inhibitor", Keystone Symposia: NF-κB: Biology and Pathology 2004, Abstract. | |
| | K. UMEZAWA, "Molecular Design and Biological Activities of NF-κB and Protein-Tyrosine Phosphatase Inhibitors", Ewha Woman's University Annual Symposium (Gosari) 2002. | |
| | Y. HORIGUCHI et al., "A Novel NF-κB Activation Inhibitor Mediated Apoptosis As a New Therapeutic Approach in Hormone-Refractory Prostate Cancer", Abstract presented at American Urological Association Annual Meeting, 2002. | |
| | A. MIYAJIMA et al., "Nuclear Factor-Kappa B Activation Inhibitor Prevents Renal Tissue Damage in Unilateral Ureteral Obstruction", Abstract presented at American Urological Association Annual Meeting, 2002. | |
| | Y. HORIGUCHI et al., "Anti-Tumo Effect of a Novel NF-κB Activation Inhibitor in Bladder Cancer Cells", Abstract presented at American Urological Association Annual Meeting, 2003. | |
| | K. UMEZAWA, "Molecular Design and Biological Activities of a New NF-κB Inhibitor, Dehydroxymethylepoxyquinomicin", Abstracts of the 7 th World Congress on Advances in Oncology and the 5 th International Symposium on Molecular Medicine, 10-12 Oct. 2002, Hersonissos, Crete, Greece. | |
| | J. NAMEKAWA et al., "Suppression of Human Breast Carcinomas in Mice by a Novel NF-κB Inhibitor DHMEQ", Abstract Presented at The 76 th Annual Meeting of the Japanese Biochemical Society. | |
| | E. SUZUKI et al., "Inhibition of Ligand-Induced Macrophage Activation by an NF-κB Inhibitor, DHMEQ", Abstract Presented at The 76 th Annual Meeting of the Japanese Biochemical Society. | |
| | T. KUBOTA et al., "Application of an NF-κB Inhibitor to the Therapy of SLE", Program and Abstracts of the American College of Rheumatology 67 th Annual Scientific Meeting; October 23-28, 2003; Orlando, FL. Abstract. | |
| | Y. HORIGUCHI et al., "Prevention of Cancer Cachexia by a Novel NFκB Inhibitor in Nude Mice", Proceedings of the American Association for Cancer Research 95 th Annual Meeting. Abstract. | |
| | Y. HORIGUCHI, et al., "Suppression of Hormone-Refractory Prostate Cancer by a Novel NF-κB Inhibitor in Nude Mice", Proceedings of the American Association for Cancer Research 93 rd Annual Meeting. Abstract 2163. | |
| | A. ARIGA et al., "Inhibition of TNF-Alpha-Induced NF-Kappa B Functions by a Synthetic Epoxyquinomicin Analogue", Proceedings of the American Association for Cancer Research 92 nd Annual Meeting. Abstract 2111. | |
| | E. KIKUCHI et al., "A Novel NF-κB Activation Inhibitor-Mediated Apoptosis as a New Therapeutic Approach in Hormone-Refractory Prostate Cancer", The 47 th Annual Congress of the Japan Section of the | |



| | | | | |
|---|---|----|--------------------------|----------------------|
| IDS Form PTO/SB/08: Substitute for form 1449A/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | Application Number | 10/567,432 |
| | | | Filing Date | February 6, 2006 |
| | | | First Named Inventor | Kazuo Umezawa et al. |
| | | | Art Unit | Unassigned |
| | | | Examiner Name | Unassigned |
| | | | Attorney Docket Number | 9707.0007 |
| Sheet | 5 | of | 5 | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--|---|--|
| | | International College of Surgeons, 2001, Abstract. | |
| | | Y. HORIGUCHI et al., "NF-κB Function Inhibitor, DHMEQ as a Treatment Option for Advanced Urological Cancer", The 92 nd Annual Meeting of the Japanese Urological Association, 2004, Abstract. | |
| | | R. LANGEN et al., "Inflammatory Cytokines Inhibit Myogenic Differentiation Through Activation of Nuclear Factor-κB", FASEB J. 15, 1169-80, 2001. | |
| | | L. XU et al., "Human Lupus T Cells Resist Inactivation and Escape Death by Upregulating COX-2", Nature Medicine Vol. 10, No. 4, April 2004, pp. 411-415. | |
| | | K. UMEZAWA, "Screening of Naturally Occurring NF-kappa B Inhibitors and Application to Mechanistic Studies", The 81 st Annual Meeting of the Physiological Society of Japan, 2004, Abstract. | |
| | | K. SAKURAI et al., "Study on the Inhibition of Adhesion Molecule Expression on the Endothelial Cells by NF-κB Inhibitor, DHMEQ", The XVIIth Annual Meeting of the International Society for Laboratory Hematology (ISLH), 2004, Abstract. | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.